Literature DB >> 26358858

Multicenter clinical evaluation of three commercial reagent kits based on the interferon-gamma release assay for the rapid diagnosis of tuberculosis in China.

Yan Qiu1, Yansen Wang2, Nan Lin3, Mingxiang Huang4, Yunhong Tan5, Qing Wang6, Yi Jiang3, Haican Liu3, Jiao Liu3, Jingrui Zhang3, Jue Wang4, Xinchan Chen5, Dongping Wang6, Guilian Li3, Zhongnan Chen4, Lishui Zhang5, Dixun Bao5, Lili Zhao3, Chaxiang Guan7, Kanlgin Wan8.   

Abstract

OBJECTIVE: To evaluate the performance of three interferon-gamma release assay (IGRA) kits in detecting Mycobacterium tuberculosis infection in China.
METHODS: A multicenter clinical trial was used to compare the effectiveness and application of the three kits. A total of 1026 participants were enrolled at three hospitals, including 597 tuberculosis (TB) patients diagnosed clinically (517 patients with pulmonary TB and 80 patients with extrapulmonary TB) and 429 negative controls (244 patients with pulmonary disease but not TB, or with non-tuberculosis mycobacterial lung diseases, and 185 healthy people). Detection performance indicators including sensitivity, specificity, and the Youden index (YI) were used to evaluate performance.
RESULTS: Through bacterial culture evaluation, 224 of the 517 pulmonary TB patients were positive and all 429 negative controls were negative. When the gold standard bacterial methods were used, the sensitivity, specificity, and YI were 89.7% (201/224), 91.1% (391/429), and 0.81 for T-SPOT.TB, 86.2% (193/224), 87.2% (374/429), and 0.73 for QB-SPOT, and 83.9% (188/224), 88.6% (380/429), and 0.73 for TB-IGRA, respectively. There were no significant differences in the sensitivity and specificity of the three kits.
CONCLUSIONS: The results showed that the three kits had very high sensitivity and specificity and exhibited a good performance for the detection of M. tuberculosis infection.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  China; Diagnosis; Evaluation; Interferon-gamma release assay; Tuberculosis

Mesh:

Substances:

Year:  2015        PMID: 26358858     DOI: 10.1016/j.ijid.2015.09.004

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  6 in total

1.  Diagnostic accuracy of interferon-gamma release assays for diagnosis of smear-negative pulmonary tuberculosis: a systematic review and meta-analysis.

Authors:  Tananchai Petnak; Dararat Eksombatchai; Supavit Chesdachai; Ploypin Lertjitbanjong; Pahnwat Taweesedt; Angsupat Pornchai; Charat Thongprayoon; Larry J Prokop; Zhen Wang
Journal:  BMC Pulm Med       Date:  2022-06-06       Impact factor: 3.320

2.  Analysis of Factors Influencing Diagnostic Accuracy of T-SPOT.TB for Active Tuberculosis in Clinical Practice.

Authors:  Lifan Zhang; Xiaochun Shi; Yueqiu Zhang; Yao Zhang; Feifei Huo; Baotong Zhou; Guohua Deng; Xiaoqing Liu
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

3.  Factors associated with negative T-SPOT.TB results among smear-negative tuberculosis patients in China.

Authors:  Wanli Kang; Meiying Wu; Kunyun Yang; A Ertai; Shucai Wu; Shujun Geng; Zhihui Li; Mingwu Li; Yu Pang; Shenjie Tang
Journal:  Sci Rep       Date:  2018-03-09       Impact factor: 4.379

4.  Clinical evaluation of the T-SPOT.TB test for detection of tuberculosis infection in northeastern Guangdong Province, China.

Authors:  Hua Zhong; Heming Wu; Zhikang Yu; Qunji Zhang; Qingyan Huang
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

5.  Combining interferon-γ release assays with lymphocyte enumeration for diagnosis of Mycobacterium tuberculosis infection.

Authors:  Dingfeng Lv; Yanqing Liu; Fei Guo; Aihua Wu; Yijun Mo; Shanshan Wang; Jinguo Chu
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

6.  Factors associated with differential T cell responses to antigens ESAT-6 and CFP-10 in pulmonary tuberculosis patients.

Authors:  Shengsheng Liu; Meiying Wu; Ertai A; Shucai Wu; Shujun Geng; Zhihui Li; Mingwu Li; Liang Li; Yu Pang; Wanli Kang; Shenjie Tang
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.